Figure 3. The expression levels of EPHA2 and AXL genes in NSCLC and SCLC tissues, as suggested by Molecular Activity Prediction algorithm (IPA) in response to miRNA influence, and the data of gene expression profiling from Oncomine.

(A) Predicted upregulation of EPHA2 gene in NSCLC tissue; (B) the lower level of expression of EPHA2 gene in SCLC; (C) Predicted downregulation of EPHA2 gene in response to treatment; (D) Oncomine reveals higher levels of EPHA2 gene expression in lung adenocarcinoma and squamous cell carcinoma than in small cell lung carcinoma, as consistent with predicted patterns. (E) Predicted upregulation of AXL gene in NSCLC; (F) the lower level of EPHA2 gene in SCLC; (G) Predicted downregulation of AXL gene in response to treatment; (H) Oncomine reveals higher levels of AXL gene expression in small cell lung carcinoma than in lung adenocarcinoma and squamous cell carcinoma, contradictory to the predicted patterns.